Media headlines about Proteon Therapeutics (NASDAQ:PRTO) have been trending somewhat negative on Sunday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Proteon Therapeutics earned a media sentiment score of -0.03 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 44.662364634768 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
PRTO has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of Proteon Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. HC Wainwright restated a “hold” rating and issued a $2.30 price objective on shares of Proteon Therapeutics in a research note on Wednesday, November 8th. Finally, Robert W. Baird restated a “hold” rating and issued a $2.00 price objective on shares of Proteon Therapeutics in a research note on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $3.20.
Shares of Proteon Therapeutics (PRTO) opened at $2.50 on Friday. Proteon Therapeutics has a 1-year low of $1.10 and a 1-year high of $2.75. The company has a market cap of $42.29, a PE ratio of -1.13 and a beta of 1.62.
In other Proteon Therapeutics news, Director James E. Flynn bought 110,557 shares of Proteon Therapeutics stock in a transaction dated Thursday, November 30th. The stock was acquired at an average cost of $1.75 per share, with a total value of $193,474.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders bought 122,852 shares of company stock valued at $216,533 over the last ninety days. Corporate insiders own 36.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Proteon Therapeutics (PRTO) Given Coverage Optimism Rating of -0.03” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/01/14/proteon-therapeutics-prto-receives-news-impact-score-of-0-03-updated-updated.html.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.